Objective To investigate the efficacy and safety of new rivaroxaban versus LMWH for prevention of EHIT.Methods The clinical date of 409 patients with great saphenous varicose(GSV)who underwent endovenous laser abla-tion(EVLA)treatment were analyzed retrospectively.The patients were divided into rivaroxaban group and LMWH group.All patients were evaluated by ultrasound at 1 and 4 weeks after the operation.The thrombotic events,bleeding events,hospitalization time,hospitalization cost and patient satisfaction were compared between the two groups.Re-sults There was no significant differences in EHIT classification and incidence of DVT between the two groups(P＞0.05).No patients had pulmonary embolism(PE).Minor bleeding events occurred in 18 of rivaroxaban group and 26 of LMWH group respectively,the difference was not statistically significant(x2=0.04,P＞0.05).No major bleeding events were observed.The hospitalization time of the rivaroxaban group was lower than the LMWH group obviously(t=5.21,P＜0.05).There was no difference in the hospitalization cost between the two groups(t=0.45,P＞0.05).The patients sat-isfaction was higher in the rivaroxaban group when compared with the LMWH group(x2=5.84,P＜0.05).Conclusion Rivaroxaban offers an oral medication approach showing no difference in preventing EHIT,DVT and PE compared with LMWH,without increased bleeding risk.Otherwise,it can improve the patients satisfaction for the reasons of lower hos-pitalization time and avoiding the pain of subcuta-neous injections.
维普
万方数据